IKT Inhibikase Therapeutics, Inc.

NASDAQ
$2.06

Inhibikase Therapeutics, Inc. (IKT) is expected to report earnings on November 16, 2026, after the market close. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.5% since its last earnings release on August 11, 2026.

Inhibikase Therapeutics Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.11)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.37

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.